CD33 and acute myeloid leukemia: Through the CD16 antigen, bispecific killer engager-containing anti-CD16 and anti-CD33 scFvs triggered enhanced NK cell cytotoxicity against CD33+ HL60 cell line and de novo AML cells independent of the E:T ratio [219].